Literature DB >> 29463561

Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.

Jan Hülsdünker1,2,3, Katja J Ottmüller4,5, Hannes P Neeff6, Motoko Koyama7,8, Zhan Gao9, Oliver S Thomas1,2,3, Marie Follo1, Ali Al-Ahmad10, Gabriele Prinz1, Sandra Duquesne1, Heide Dierbach1, Susanne Kirschnek11, Tim Lämmermann12, Martin J Blaser9, Brian T Fife13, Bruce R Blazar14, Andreas Beilhack4,15,16, Geoffrey R Hill7,8, Georg Häcker11, Robert Zeiser1.   

Abstract

Conditioning-induced damage of the intestinal tract plays a critical role during the onset of acute graft-versus-host disease (GVHD). Therapeutic interference with these early events of GVHD is difficult, and currently used immunosuppressive drugs mainly target donor T cells. However, not donor T cells but neutrophils reach the sites of tissue injury first, and therefore could be a potential target for GVHD prevention. A detailed analysis of neutrophil fate during acute GVHD and the effect on T cells is difficult because of the short lifespan of this cell type. By using a novel photoconverter reporter system, we show that neutrophils that had been photoconverted in the ileum postconditioning later migrated to mesenteric lymph nodes (mLN). This neutrophil migration was dependent on the intestinal microflora. In the mLN, neutrophils colocalized with T cells and presented antigen on major histocompatibility complex (MHC)-II, thereby affecting T cell expansion. Pharmacological JAK1/JAK2 inhibition reduced neutrophil influx into the mLN and MHC-II expression, thereby interfering with an early event in acute GVHD pathogenesis. In agreement with this finding, neutrophil depletion reduced acute GVHD. We conclude that neutrophils are attracted to the ileum, where the intestinal barrier is disrupted, and then migrate to the mLN, where they participate in alloantigen presentation. JAK1/JAK2-inhibition can interfere with this process, which provides a potential therapeutic strategy to prevent early events of tissue damage-related innate immune cell activation and, ultimately, GVHD.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29463561      PMCID: PMC5909763          DOI: 10.1182/blood-2017-10-812891

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

2.  Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium.

Authors:  Marzena Schiwon; Christina Weisheit; Lars Franken; Sebastian Gutweiler; Akanksha Dixit; Catherine Meyer-Schwesinger; Judith-Mira Pohl; Nicholas J Maurice; Stephanie Thiebes; Kristina Lorenz; Thomas Quast; Martin Fuhrmann; Georg Baumgarten; Martin J Lohse; Ghislain Opdenakker; Jürgen Bernhagen; Rick Bucala; Ulf Panzer; Waldemar Kolanus; Hermann-Josef Gröne; Natalio Garbi; Wolfgang Kastenmüller; Percy A Knolle; Christian Kurts; Daniel R Engel
Journal:  Cell       Date:  2014-01-30       Impact factor: 41.582

3.  SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage.

Authors:  Martin Giroux; Jean-Sébastien Delisle; Simon-David Gauthier; Krista M Heinonen; Julie Hinsinger; Billy Houde; Louis Gaboury; Sylvie Brochu; Jiangping Wu; Marie-Josée Hébert; Claude Perreault
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

4.  Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.

Authors:  Konrad Wilhelm; Jayanthi Ganesan; Tobias Müller; Christoph Dürr; Melanie Grimm; Andreas Beilhack; Christine D Krempl; Stephan Sorichter; Ulrike V Gerlach; Eva Jüttner; Alf Zerweck; Frank Gärtner; Patrizia Pellegatti; Francesco Di Virgilio; Davide Ferrari; Neeraja Kambham; Paul Fisch; Jürgen Finke; Marco Idzko; Robert Zeiser
Journal:  Nat Med       Date:  2010-11-21       Impact factor: 53.440

5.  CCR2 Expression in Neutrophils Plays a Critical Role in Their Migration Into the Joints in Rheumatoid Arthritis.

Authors:  Jhimmy Talbot; Francine J Bianchini; Danilele C Nascimento; Rene D R Oliveira; Fabricio O Souto; Larissa G Pinto; Raphael S Peres; Jaqueline R Silva; Sergio C L Almeida; Paulo Louzada-Junior; Thiago M Cunha; Fernando Q Cunha; Jose C Alves-Filho
Journal:  Arthritis Rheumatol       Date:  2015-07       Impact factor: 10.995

6.  Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100.

Authors:  Franziska Leonhardt; Sebastian Grundmann; Martin Behe; Franziska Bluhm; Rebecca A Dumont; Friederike Braun; Melpomeni Fani; Katarina Riesner; Gabriele Prinz; Anne-Kathrin Hechinger; Ulrike V Gerlach; Heide Dierbach; Olaf Penack; Annette Schmitt-Gräff; Jürgen Finke; Wolfgang A Weber; Robert Zeiser
Journal:  Blood       Date:  2013-01-17       Impact factor: 22.113

7.  Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

Authors:  Nicolaus Kröger; Carlos Solano; Christine Wolschke; Giuseppe Bandini; Francesca Patriarca; Massimo Pini; Arnon Nagler; Carmine Selleri; Antonio Risitano; Giuseppe Messina; Wolfgang Bethge; Jaime Pérez de Oteiza; Rafael Duarte; Angelo Michele Carella; Michele Cimminiello; Stefano Guidi; Jürgen Finke; Nicola Mordini; Christelle Ferra; Jorge Sierra; Domenico Russo; Mario Petrini; Giuseppe Milone; Fabio Benedetti; Marion Heinzelmann; Domenico Pastore; Manuel Jurado; Elisabetta Terruzzi; Franco Narni; Andreas Völp; Francis Ayuk; Tapani Ruutu; Francesca Bonifazi
Journal:  N Engl J Med       Date:  2016-01-07       Impact factor: 91.245

8.  Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression.

Authors:  Gérard Socié; Jean-Yves Mary; Marc Lemann; Marjan Daneshpouy; Philippe Guardiola; Véronique Meignin; Lionel Ades; Hélène Esperou; Patricia Ribaud; Agnés Devergie; Eliane Gluckman; Jean-Claude Ameisen; Anne Janin
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

Review 9.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

10.  The Nlrp3 inflammasome regulates acute graft-versus-host disease.

Authors:  Dragana Jankovic; Jayanthi Ganesan; Michael Bscheider; Natalie Stickel; Felix C Weber; Greta Guarda; Marie Follo; Dietmar Pfeifer; Aubry Tardivel; Kristina Ludigs; Abdellatif Bouazzaoui; Katrin Kerl; Julius C Fischer; Tobias Haas; Annette Schmitt-Gräff; Anand Manoharan; Leonard Müller; Jürgen Finke; Stefan F Martin; Oliver Gorka; Christian Peschel; Jürgen Ruland; Marco Idzko; Justus Duyster; Ernst Holler; Lars E French; Hendrik Poeck; Emmanuel Contassot; Robert Zeiser
Journal:  J Exp Med       Date:  2013-08-26       Impact factor: 14.307

View more
  37 in total

1.  Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.

Authors:  Seungwon An; Ilangovan Raju; Bayasgalan Surenkhuu; Ji-Eun Kwon; Shilpa Gulati; Muge Karaman; Anubhav Pradeep; Satyabrata Sinha; Christine Mun; Sandeep Jain
Journal:  Ocul Surf       Date:  2019-04-06       Impact factor: 5.033

Review 2.  Biology-driven developments in the therapy of acute graft-versus-host disease.

Authors:  Robert Zeiser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Recent advances on the crosstalk between neutrophils and B or T lymphocytes.

Authors:  Sara Costa; Dalila Bevilacqua; Marco A Cassatella; Patrizia Scapini
Journal:  Immunology       Date:  2018-10-10       Impact factor: 7.397

4.  Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia.

Authors:  Nimitha R Mathew; Janaki M Vinnakota; Petya Apostolova; Daniel Erny; Shaimaa Hamarsheh; Geoffroy Andrieux; Jung-Seok Kim; Kathrin Hanke; Tobias Goldmann; Louise Chappell-Maor; Nadia El-Khawanky; Gabriele Ihorst; Dominik Schmidt; Justus Duyster; Jürgen Finke; Thomas Blank; Melanie Boerries; Bruce R Blazar; Steffen Jung; Marco Prinz; Robert Zeiser
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 5.  The gut microbiota and graft-versus-host disease.

Authors:  David N Fredricks
Journal:  J Clin Invest       Date:  2019-05-01       Impact factor: 14.808

6.  Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells.

Authors:  Jessica Stokes; Emely A Hoffman; Megan S Molina; Jelena Eremija; Nicolas Larmonier; Yi Zeng; Emmanuel Katsanis
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-13       Impact factor: 5.742

7.  MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota.

Authors:  Motoko Koyama; Pamela Mukhopadhyay; Iona S Schuster; Andrea S Henden; Jan Hülsdünker; Antiopi Varelias; Marie Vetizou; Rachel D Kuns; Renee J Robb; Ping Zhang; Bruce R Blazar; Ranjeny Thomas; Jakob Begun; Nicola Waddell; Giorgio Trinchieri; Robert Zeiser; Andrew D Clouston; Mariapia A Degli-Esposti; Geoffrey R Hill
Journal:  Immunity       Date:  2019-09-18       Impact factor: 31.745

Review 8.  Resolution of acute intestinal graft-versus-host disease.

Authors:  Sindhu Thiagarajan; Markus F Neurath; Kai Hildner
Journal:  Semin Immunopathol       Date:  2019-10-31       Impact factor: 9.623

9.  Immunization against poly-N-acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity.

Authors:  Jan Hülsdünker; Oliver S Thomas; Eileen Haring; Susanne Unger; Nicolás Gonzalo Núñez; Sonia Tugues; Zhan Gao; Sandra Duquesne; Colette Cywes-Bentley; Ozlem Oyardi; Susanne Kirschnek; Annette Schmitt-Graeff; Oliver Pabst; Christian Koenecke; Justus Duyster; Petya Apostolova; Martin J Blaser; Burkhard Becher; Gerald B Pier; Georg Häcker; Robert Zeiser
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-16       Impact factor: 11.205

10.  The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease.

Authors:  Robert Zeiser; Gérard Socié
Journal:  Blood Adv       Date:  2020-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.